Carboplatino Accord 10 mg/ml concentrado para solución para perfusión EFG

DRUG2 trials

Sponsors

Summit Therapeutics Inc., Oncomatryx Biopharma S.L.

Conditions

Advanced/Metastatic Non-squamous Non-Small Cell Lung CancerPatients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment

Phase 1

Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and Tislelizumab in Patients with Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer

Not yet recruitingCTIS2025-521989-95-00

Oncomatryx Biopharma S.L.Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer

Target: 88Updated: 2025-12-12

Phase 3

A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi)

Active, not recruitingCTIS2023-504434-22-00

Summit Therapeutics Inc.Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment

Start: 2023-10-03Target: 45Updated: 2025-12-16